

Special Issue

RNA-Based Immunotherapy

Message from the Guest Editors

This Special Issue will focus on improvements and new strategies in RNA-based immunotherapies.

Recent clinical successes, particularly with mRNA vaccines in oncology and infectious disease, have underscored the therapeutic potential of RNA immunotherapies. However, key challenges remain, including efficient in vivo delivery, targeted biodistribution, immunogenicity control, and the durability of responses. Ongoing research aims to refine delivery vectors and optimize RNA stability and translation efficiency to maximize the therapeutic benefits.

Guest Editors

Prof. Dr. Niels Schaft

Department of Dermatology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany

Dr. Jan Dörrie

Department of Dermatology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany

Deadline for manuscript submissions

31 December 2025



Immuno

an Open Access Journal
by MDPI

Impact Factor 2.5
CiteScore 3.7



mdpi.com/si/246018

Immuno
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
immuno@mdpi.com

[mdpi.com/journal/
immuno](https://mdpi.com/journal/immuno)





Immuno

an Open Access Journal
by MDPI

Impact Factor 2.5
CiteScore 3.7



[mdpi.com/journal/
immuno](https://mdpi.com/journal/immuno)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Toshihiko Torigoe
Department of Pathology, Sapporo Medical University School of
Medicine, S-1, W-17, Chuo-ku, Sapporo 060-8556, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,
and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 31.6 days after
submission; acceptance to publication is undertaken in 2.9
days (median values for papers published in this journal in
the first half of 2025).